2'-Deoxy-5-fluorocytidine

• CAT Number: M061635
• CAS Number: 10356-76-0
• Molecular Formula: C9H12FN3O4
• Molecular Weight: 245.21
• Purity: ≥95%
• Target: DNA Methyltransferase
• Storage: -20°C
• IUPAC Name: 4-amino-5-fluoro-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
• InChI: InChI=1S/C9H12FN3O4/c10-4-2-13(9(16)12-8(4)11)7-1-5(15)6(3-14)17-7/h2,5-7,14-15H,1,3H2,(H2,11,12,16)/t5-,6+,7+/m0/s1
• InChIKey: IDYKCXHJJGMAEV-RRKCRQDMSA-N
• SMILES: C1C(C(OC1N2C=C(C(=NC2=O)N)F)CO)O

FdCyd is a DNA methyltransferase (DNMT) inhibitor potentially for the treatment of solid tumours.

Reference

1: Holleran JL, Eiseman JL, Parise RA, Kummar S, Beumer JH. LC-MS/MS assay for the quantitation of FdCyd and its metabolites FdUrd and FU in human plasma. J Pharm Biomed Anal. 2016 Sep 10;129:359-66. doi: 10.1016/j.jpba.2016.07.027. PubMed PMID: 27454087; PubMed Central PMCID: PMC5003709.2: Beumer JH, Parise RA, Newman EM, Doroshow JH, Synold TW, Lenz HJ, Egorin MJ. Concentrations of the DNA methyltransferase inhibitor 5-fluoro-2/’-deoxycytidine (FdCyd) and its cytotoxic metabolites in plasma of patients treated with FdCyd and tetrahydrouridine (THU). Cancer Chemother Pharmacol. 2008 Jul;62(2):363-8. PubMed PMID: 17899082.3: Newman EM, Morgan RJ, Kummar S, Beumer JH, Blanchard MS, Ruel C, El-Khoueiry AB, Carroll MI, Hou JM, Li C, Lenz HJ, Eiseman JL, Doroshow JH. A phase I, pharmacokinetic, and pharmacodynamic evaluation of the DNA methyltransferase inhibitor 5-fluoro-2/’-deoxycytidine, administered with tetrahydrouridine. Cancer Chemother Pharmacol. 2015 Mar;75(3):537-46. doi: 10.1007/s00280-014-2674-7. PubMed PMID: 25567350; PubMed Central PMCID: PMC4344391.4: Holleran JL, Beumer JH, McCormick DL, Johnson WD, Newman EM, Doroshow JH, Kummar S, Covey JM, Davis M, Eiseman JL. Oral and intravenous pharmacokinetics of 5-fluoro-2/’-deoxycytidine and THU in cynomolgus monkeys and humans. Cancer Chemother Pharmacol. 2015 Oct;76(4):803-11. doi: 10.1007/s00280-015-2857-x. PubMed PMID: 26321472; PubMed Central PMCID: PMC4573928.5: Guo D, Myrdal PB, Karlage KL, O/’Connell SP, Wissinger TJ, Tabibi SE, Yalkowsky SH. Stability of 5-fluoro-2/’-deoxycytidine and tetrahydrouridine in combination. AAPS PharmSciTech. 2010 Mar;11(1):247-52. doi: 10.1208/s12249-010-9383-2. PubMed PMID: 20151336; PubMed Central PMCID: PMC2850501.6: Beumer JH, Eiseman JL, Parise RA, Joseph E, Holleran JL, Covey JM, Egorin MJ. Pharmacokinetics, metabolism, and oral bioavailability of the DNA methyltransferase inhibitor 5-fluoro-2/’-deoxycytidine in mice. Clin Cancer Res. 2006 Dec 15;12(24):7483-91. PubMed PMID: 17138702.7: Morfouace M, Nimmervoll B, Boulos N, Patel YT, Shelat A, Freeman BB 3rd, Robinson GW, Wright K, Gajjar A, Stewart CF, Gilbertson RJ, Roussel MF. Preclinical studies of 5-fluoro-2/’-deoxycytidine and tetrahydrouridine in pediatric brain tumors. J Neurooncol. 2016 Jan;126(2):225-34. doi: 10.1007/s11060-015-1965-0. PubMed PMID: 26518542; PubMed Central PMCID: PMC4718940.8: Pan Y, Daito T, Sasaki Y, Chung YH, Xing X, Pondugula S, Swamidass SJ, Wang T, Kim AH, Yano H. Inhibition of DNA Methyltransferases Blocks Mutant Huntingtin-Induced Neurotoxicity. Sci Rep. 2016 Aug 12;6:31022. doi: 10.1038/srep31022. PubMed PMID: 27516062; PubMed Central PMCID: PMC4981892.9: Mekras JA, Boothman DA, Perez LM, Greer S. Use of 5-fluorodeoxycytidine and tetrahydrouridine to exploit high levels of deoxycytidylate deaminase in tumors to achieve DNA- and target-directed therapies. Cancer Res. 1984 Jun;44(6):2551-60. PubMed PMID: 6539164.10: Boothman DA, Briggle TV, Greer S. Protective, tumor-selective dual pathway activation of 5-fluoro-2/’-deoxycytidine provided by tetrahydrouridine in mice bearing mammary adenocarcinoma-755. Cancer Res. 1987 May 1;47(9):2344-53. PubMed PMID: 2436761.11: Kaysen J, Spriggs D, Kufe D. Incorporation of 5-fluorodeoxycytidine and metabolites into nucleic acids of human MCF-7 breast carcinoma cells. Cancer Res. 1986 Sep;46(9):4534-8. PubMed PMID: 2425957.12: Boothman DA, Briggle TV, Greer S. Tumor-selective metabolism of 5-fluoro-2/’-deoxycytidine coadministered with tetrahydrouridine compared to 5-fluorouracil in mice bearing Lewis lung carcinoma. Cancer Res. 1987 May 1;47(9):2354-62. PubMed PMID: 2952263.13: Li LS, Morales JC, Veigl M, Sedwick D, Greer S, Meyers M, Wagner M, Fishel R, Boothman DA. DNA mismatch repair (MMR)-dependent 5-fluorouracil cytotoxicity and the potential for new therapeutic targets. Br J Pharmacol. 2009 Oct;158(3):679-92. doi: 10.1111/j.1476-5381.2009.00423.x. Review. PubMed PMID: 19775280; PubMed Central PMCID: PMC2765589.14: Vandamme B, Liebaers I, Hens L, Bernheim JL, Roobol C. The role of fluorinated pyrimidine analogues in the induction of the in vitro expression of the fragile X chromosome. Hum Genet. 1988 Aug;79(4):341-6. PubMed PMID: 2970425.15: Newman EM, Santi DV. Metabolism and mechanism of action of 5-fluorodeoxycytidine. Proc Natl Acad Sci U S A. 1982 Nov;79(21):6419-23. PubMed PMID: 6959127; PubMed Central PMCID: PMC347137.16: Iigo M, Yamaizumi Z, Nishimura S, Hoshi A. Elevation of plasma levels of fluorinated pyrimidines by guanosine 5/’-monophosphate. Cancer Chemother Pharmacol. 1987;20(1):1-4. PubMed PMID: 3040286.17: Briggle TV, Boothman DA, Pfaffenberger CD, Greer S. Analysis of 5-fluoro-2/’-deoxycytidine and 5-trifluoromethyl-2/’-deoxycytidine and their related antimetabolites by high-performance liquid chromatography. J Chromatogr. 1986 Sep 5;381(2):343-55. PubMed PMID: 2944908.18: Osterman DG, DePillis GD, Wu JC, Matsuda A, Santi DV. 5-Fluorocytosine in DNA is a mechanism-based inhibitor of HhaI methylase. Biochemistry. 1988 Jul 12;27(14):5204-10. PubMed PMID: 3167042.19: Janion C. On the ability of Salmonella typhimurium cells to form deoxycytidine nucleotides. Mol Gen Genet. 1977 Jun 8;153(2):179-83. PubMed PMID: 329115.20: De Clercq E, Bères J, Bentrude WG. Potent activity of 5-fluoro-2/’-deoxyuridine and related compounds against thymidine kinase-deficient (TK-) herpes simplex virus: targeted at thymidylate synthase. Mol Pharmacol. 1987 Aug;32(1):286-92. PubMed PMID: 3039343.